Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Management of aggressive B cell NHLs in the AYA population: an adult versus pediatric perspective.

Dunleavy K, Gross TG.

Blood. 2018 Jun 12. pii: blood-2018-02-778480. doi: 10.1182/blood-2018-02-778480. [Epub ahead of print]

PMID:
29895666
2.

Liquid biopsy for Hodgkin: a game changer?

Dunleavy K.

Blood. 2018 May 31;131(22):2407-2408. doi: 10.1182/blood-2018-04-840819. No abstract available.

PMID:
29853457
3.

End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted-EPOCH-R: A paradigm shift in clinical decision making.

Melani C, Advani R, Roschewski M, Walters KM, Chen CC, Baratto L, Ahlman MA, Miljkovic MD, Steinberg SM, Lam J, Shovlin M, Dunleavy K, Pittaluga S, Jaffe ES, Wilson WH.

Haematologica. 2018 May 10. pii: haematol.2018.192492. doi: 10.3324/haematol.2018.192492. [Epub ahead of print]

4.

Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma.

Dunleavy K, Erdmann T, Lenz G.

Cancer Treat Rev. 2018 Apr;65:41-46. doi: 10.1016/j.ctrv.2018.01.002. Epub 2018 Feb 1. Review.

PMID:
29549872
5.

Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes.

Kahn JM, Ozuah NW, Dunleavy K, Henderson TO, Kelly K, LaCasce A.

Blood Adv. 2017 Oct 10;1(22):1945-1958. doi: 10.1182/bloodadvances.2017008748. eCollection 2017 Oct 10. Review.

6.

Ovarian vein thrombus: to treat or not to treat?

Plastini T, Henry D, Dunleavy K.

Blood Adv. 2017 Jun 22;1(15):1120-1123. doi: 10.1182/bloodadvances.2017006577. eCollection 2017 Jun 27. No abstract available.

7.

Spore forming bacteria infections and people who inject drugs: Implications for harm reduction.

Dunleavy K, Munro A, Roy K, Hutchinson S, Palmateer N, Knox T, Goldberg D, Hope V, Campbell J, Hamilton E, Liddell D, Penrice G, Taylor A.

Int J Drug Policy. 2018 Mar;53:45-54. doi: 10.1016/j.drugpo.2017.12.001. Epub 2017 Dec 24.

PMID:
29281807
8.

Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies.

Dunleavy K.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):298-303. doi: 10.1182/asheducation-2017.1.298. Review.

PMID:
29222270
9.

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group.

Uldrick TS, Ison G, Rudek MA, Noy A, Schwartz K, Bruinooge S, Schenkel C, Miller B, Dunleavy K, Wang J, Zeldis J, Little RF.

J Clin Oncol. 2017 Nov 20;35(33):3774-3780. doi: 10.1200/JCO.2017.73.7338. Epub 2017 Oct 2.

10.

Advances in the management of primary central nervous system lymphoma.

Dunleavy K.

Clin Adv Hematol Oncol. 2017 Sep;15(9):677-679. No abstract available.

PMID:
28949937
11.

Adult T-Cell Lymphoma/Leukemia: Novel Biologic Insights and New Directions in Treatment.

Dunleavy K.

J Oncol Pract. 2017 Aug;13(8):493-494. doi: 10.1200/JOP.2017.024323. No abstract available.

PMID:
28796967
12.

Leadership Development of Rehabilitation Professionals in a Low-Resource Country: A Transformational Leadership, Project-Based Model.

Pascal MR, Mann M, Dunleavy K, Chevan J, Kirenga L, Nuhu A.

Front Public Health. 2017 Jun 23;5:143. doi: 10.3389/fpubh.2017.00143. eCollection 2017.

13.

MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.

Lai C, Roschewski M, Melani C, Pittaluga S, Shovlin M, Steinberg SM, Dunleavy K, Pack S, Jaffe ES, Wilson WH.

Leuk Lymphoma. 2018 Feb;59(2):505-508. doi: 10.1080/10428194.2017.1339882. Epub 2017 Jun 22. No abstract available.

PMID:
28641474
14.

Management of Primary Mediastinal B-Cell Lymphoma and Gray Zone Lymphoma.

Dunleavy K.

Oncology (Williston Park). 2017 Jun 15;31(6):499-501.

15.

Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.

Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, Yang Y, Cole DE, Melani C, Higham CS, Desai JV, Ceribelli M, Chen L, Thomas CJ, Little RF, Gea-Banacloche J, Bhaumik S, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Heiss J, Lucas N, Steinberg SM, Staudt LM, Wilson WH.

Cancer Cell. 2017 Jun 12;31(6):833-843.e5. doi: 10.1016/j.ccell.2017.04.012. Epub 2017 May 25.

16.

Unraveling Castleman: progress in a complex process.

Dunleavy K.

Blood. 2017 Mar 23;129(12):1570. doi: 10.1182/blood-2017-02-764654. No abstract available.

17.

Application of a contextual instructional framework in a continuing professional development training program for physiotherapists in Rwanda.

Dunleavy K, Chevan J, Sander AP, Gasherebuka JD, Mann M.

Disabil Rehabil. 2018 Jun;40(13):1600-1608. doi: 10.1080/09638288.2017.1300692. Epub 2017 Mar 22.

PMID:
28325084
18.

Association between harm reduction intervention uptake and skin and soft tissue infections among people who inject drugs.

Dunleavy K, Munro A, Roy K, Hutchinson S, Palmateer N, Knox T, Goldberg D, Taylor A.

Drug Alcohol Depend. 2017 May 1;174:91-97. doi: 10.1016/j.drugalcdep.2017.01.020. Epub 2017 Mar 6.

PMID:
28319754
19.

DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in Presentation.

Dimitriades VR, Devlin V, Pittaluga S, Su HC, Holland SM, Wilson W, Dunleavy K, Shah NN, Freeman AF.

Front Pediatr. 2017 Feb 28;5:38. doi: 10.3389/fped.2017.00038. eCollection 2017.

20.

Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.

Stone J, Martin NK, Hickman M, Hutchinson SJ, Aspinall E, Taylor A, Munro A, Dunleavy K, Peters E, Bramley P, Hayes PC, Goldberg DJ, Vickerman P.

Addiction. 2017 Jul;112(7):1302-1314. doi: 10.1111/add.13783. Epub 2017 Mar 3.

21.

Update on Burkitt Lymphoma.

Dunleavy K, Little RF, Wilson WH.

Hematol Oncol Clin North Am. 2016 Dec;30(6):1333-1343. doi: 10.1016/j.hoc.2016.07.009. Review.

PMID:
27888884
22.

Oxidation increases the strength of the methionine-aromatic interaction.

Lewis AK, Dunleavy KM, Senkow TL, Her C, Horn BT, Jersett MA, Mahling R, McCarthy MR, Perell GT, Valley CC, Karim CB, Gao J, Pomerantz WC, Thomas DD, Cembran A, Hinderliter A, Sachs JN.

Nat Chem Biol. 2016 Oct;12(10):860-6. doi: 10.1038/nchembio.2159. Epub 2016 Aug 22.

23.

Synaptotagmin I's Intrinsically Disordered Region Interacts with Synaptic Vesicle Lipids and Exerts Allosteric Control over C2A.

Fealey ME, Mahling R, Rice AM, Dunleavy K, Kobany SE, Lohese KJ, Horn B, Hinderliter A.

Biochemistry. 2016 May 31;55(21):2914-26. doi: 10.1021/acs.biochem.6b00085. Epub 2016 May 18.

PMID:
27191789
24.

Female fertility following dose-adjusted EPOCH-R chemotherapy in primary mediastinal B-cell lymphomas.

Gharwan H, Lai C, Grant C, Dunleavy K, Steinberg SM, Shovlin M, Fojo T, Wilson WH.

Leuk Lymphoma. 2016 Jul;57(7):1616-24. doi: 10.3109/10428194.2015.1118476. Epub 2016 May 17.

PMID:
27183887
25.

Double hit lymphoma: from biology to therapeutic implications.

Burotto M, Berkovits A, Dunleavy K.

Expert Rev Hematol. 2016 Jul;9(7):669-78. doi: 10.1080/17474086.2016.1182858. Epub 2016 May 21. Review.

PMID:
27166590
26.

Role of the tumor microenvironment in mature B-cell lymphoid malignancies.

Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, Bollard C, Ansell S, Curran M, Wilson WH, O'Brien S, Grant C, Little R, Zenz T, Nastoupil LJ, Dunleavy K.

Haematologica. 2016 May;101(5):531-40. doi: 10.3324/haematol.2015.139493. Review.

27.

Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.

Saba NS, Liu D, Herman SE, Underbayev C, Tian X, Behrend D, Weniger MA, Skarzynski M, Gyamfi J, Fontan L, Melnick A, Grant C, Roschewski M, Navarro A, Beà S, Pittaluga S, Dunleavy K, Wilson WH, Wiestner A.

Blood. 2016 Jul 7;128(1):82-92. doi: 10.1182/blood-2015-11-681460. Epub 2016 Apr 28.

28.

Central nervous system involvement in AIDS-related lymphomas.

Barta SK, Joshi J, Mounier N, Xue X, Wang D, Ribera JM, Navarro JT, Hoffmann C, Dunleavy K, Little RF, Wilson WH, Spina M, Galicier L, Noy A, Sparano JA.

Br J Haematol. 2016 Jun;173(6):857-66. doi: 10.1111/bjh.13998. Epub 2016 Apr 7.

29.

Optimal Management of Double-Hit Lymphoma.

Dunleavy K.

J Oncol Pract. 2016 Mar;12(3):241-2. doi: 10.1200/JOP.2015.010421. No abstract available.

PMID:
26962168
30.

Reliability and validity of cervical position measurements in individuals with and without chronic neck pain.

Dunleavy K, Neil J, Tallon A, Adamo DE.

J Man Manip Ther. 2015 Sep;23(4):188-96. doi: 10.1179/2042618614Y.0000000070.

31.

Immunomodulatory agents in mantle cell lymphoma.

Dunleavy K.

Lancet Oncol. 2016 Mar;17(3):262-3. doi: 10.1016/S1470-2045(16)00027-9. Epub 2016 Feb 16. No abstract available.

PMID:
26899779
32.

Discordant bone marrow involvement in non-Hodgkin lymphoma.

Brudno J, Tadmor T, Pittaluga S, Nicolae A, Polliack A, Dunleavy K.

Blood. 2016 Feb 25;127(8):965-70. doi: 10.1182/blood-2015-06-651968. Epub 2015 Dec 17. Review.

33.

Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL.

Dunleavy K.

Curr Treat Options Oncol. 2015 Dec;16(12):58. doi: 10.1007/s11864-015-0374-0.

PMID:
26634708
34.

Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma.

Dunleavy K, Pittaluga S, Shovlin M, Roschewski M, Lai C, Steinberg SM, Jaffe ES, Wilson WH.

Haematologica. 2016 Jan;101(1):e27-9. doi: 10.3324/haematol.2015.131151. Epub 2015 Oct 30. No abstract available.

35.

Comparative effectiveness of Pilates and yoga group exercise interventions for chronic mechanical neck pain: quasi-randomised parallel controlled study.

Dunleavy K, Kava K, Goldberg A, Malek MH, Talley SA, Tutag-Lehr V, Hildreth J.

Physiotherapy. 2016 Sep;102(3):236-42. doi: 10.1016/j.physio.2015.06.002. Epub 2015 Aug 13.

PMID:
26435334
36.

Secondary diffuse large B-cell lymphoma of the central nervous system: the need for better predictors.

Roschewski M, Dunleavy K.

Leuk Lymphoma. 2015 Jun;56(6):1583-4. doi: 10.3109/10428194.2015.1016936. No abstract available.

PMID:
26099732
37.

Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.

Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, Shovlin M, Jaffe ES, Staudt LM, Lai C, Steinberg SM, Chen CC, Zheng J, Willis TD, Faham M, Wilson WH.

Lancet Oncol. 2015 May;16(5):541-9. doi: 10.1016/S1470-2045(15)70106-3. Epub 2015 Apr 1. Erratum in: Lancet Oncol. 2015 May;16(5):e199.

38.

Emerging biological insights and novel treatment strategies in primary mediastinal large B-cell lymphoma.

Dunleavy K, Steidl C.

Semin Hematol. 2015 Apr;52(2):119-25. doi: 10.1053/j.seminhematol.2015.01.002. Epub 2015 Jan 17. Review.

PMID:
25805591
39.

Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma.

Okoli TC, Peer CJ, Dunleavy K, Figg WD.

Cancer Biol Ther. 2015;16(2):204-6. doi: 10.1080/15384047.2014.1002369.

40.

Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma.

Leshchenko VV, Kuo PY, Jiang Z, Weniger MA, Overbey J, Dunleavy K, Wilson WH, Wiestner A, Parekh S.

Oncotarget. 2015 Sep 29;6(29):27332-42. doi: 10.18632/oncotarget.2903.

41.

Double-hit lymphomas: current paradigms and novel treatment approaches.

Dunleavy K.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):107-12. doi: 10.1182/asheducation-2014.1.107. Epub 2014 Nov 18. Review.

PMID:
25696842
42.

Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma.

Barta SK, Samuel MS, Xue X, Wang D, Lee JY, Mounier N, Ribera JM, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Little RF, Dunleavy K, Wilson WH, Wyen C, Remick SC, Kaplan LD, Ratner L, Noy A, Sparano JA.

Ann Oncol. 2015 May;26(5):958-66. doi: 10.1093/annonc/mdv036. Epub 2015 Jan 28. Review.

43.

FDG PET-CT in follicular lymphoma: a case-based evidence review.

Smith SD, Redman M, Dunleavy K.

Blood. 2015 Feb 12;125(7):1078-82. doi: 10.1182/blood-2014-11-537522. Epub 2014 Dec 19. Review. No abstract available.

44.

Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?

Dunleavy K, Wilson WH.

Blood. 2015 Jan 1;125(1):33-9. doi: 10.1182/blood-2014-05-575092. Epub 2014 Dec 11. Review.

45.

Lymphomatoid granulomatosis--a single institute experience: pathologic findings and clinical correlations.

Song JY, Pittaluga S, Dunleavy K, Grant N, White T, Jiang L, Davies-Hill T, Raffeld M, Wilson WH, Jaffe ES.

Am J Surg Pathol. 2015 Feb;39(2):141-56. doi: 10.1097/PAS.0000000000000328.

46.

Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype.

Dunleavy K, Roschewski M, Wilson WH.

Clin Cancer Res. 2014 Oct 15;20(20):5182-93. doi: 10.1158/1078-0432.CCR-14-0497. Review.

47.

A new prognostic score for AIDS-related lymphomas in the rituximab-era.

Barta SK, Xue X, Wang D, Lee JY, Kaplan LD, Ribera JM, Oriol A, Spina M, Tirelli U, Boue F, Wilson WH, Wyen C, Dunleavy K, Noy A, Sparano JA.

Haematologica. 2014 Nov;99(11):1731-7. doi: 10.3324/haematol.2014.111112. Epub 2014 Aug 22.

48.

A prospective study of mediastinal gray-zone lymphoma.

Wilson WH, Pittaluga S, Nicolae A, Camphausen K, Shovlin M, Steinberg SM, Roschewski M, Staudt LM, Jaffe ES, Dunleavy K.

Blood. 2014 Sep 4;124(10):1563-9. doi: 10.1182/blood-2014-03-564906. Epub 2014 Jul 14.

49.

Appropriate management of molecular subtypes of diffuse large B-cell lymphoma.

Dunleavy K, Wilson WH.

Oncology (Williston Park). 2014 Apr;28(4):326-34. Review.

50.

Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma.

Wilson WH, Bromberg JE, Stetler-Stevenson M, Steinberg SM, Martin-Martin L, Muñiz C, Sancho JM, Caballero MD, Davidis MA, Brooimans RA, Sanchez-Gonzalez B, Salar A, González-Barca E, Ribera JM, Shovlin M, Filie A, Dunleavy K, Mehrling T, Spina M, Orfao A.

Haematologica. 2014 Jul;99(7):1228-35. doi: 10.3324/haematol.2013.101741. Epub 2014 Apr 11.

Supplemental Content

Loading ...
Support Center